Brean Murray Carret & Co. Starts Gentium (GENT) at Buy; Profitability Negates Downside Risk

Brean Murray Carret & Co. initiates coverage on Gentium (NASDAQ: GENT) with a Buy. PT $16.00.

Analyst, Brian Skorney, said, "Gentium is already profitable from defibrotide sale even though the drug is not approved anywhere in the world. We believe the current valuation is justified by the current sales projectory, with significant upside potential (100%+) upon approval in the E.U., which we expect to occur next year."

For an analyst ratings summary and ratings history on Gentium click here. For more ratings news on Gentium click here.

Shares of Gentium closed at $8.93 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
• Citi Starts China International Marine Containers A (000039:CH) at Buy
• Lake Street Starts RF Industries Ltd. (RFIL) at Buy